D4681
L-threo-Dihydrosphingosine
≥95% (TLC)
Sinónimos:
Safingol
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
| Tamaño de envase | SKU | Disponibilidad | Precio |
|---|---|---|---|
| 1 mg | Disponible para enviar HOYdesdeMILWAUKEE | $224.00 |
Acerca de este artículo
Fórmula empírica (notación de Hill):
C18H39NO2
Número CAS:
Peso molecular:
301.51
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352211
MDL number:
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleQuality Level
assay
≥95% (TLC)
form
powder
storage temp.
−20°C
SMILES string
CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO
InChI
1S/C18H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)17(19)16-20/h17-18,20-21H,2-16,19H2,1H3/t17-,18-/m0/s1
InChI key
OTKJDMGTUTTYMP-ROUUACIJSA-N
Biochem/physiol Actions
Sphingosine kinase inhibitor; protein kinase C alpha (PKCα) -specific inhibitor; Sphingosine analog; potentiates the effect of doxorubicin (DOX) in tumor-bearing animals.
1 of 1
Este artículo | |||
|---|---|---|---|
| assay ≥95% (TLC) | assay ≥98% (TLC) | assay ≥98% (TLC) | assay ≥95% (TLC) |
| form powder | form powder | form waxy solid | form powder |
| Quality Level 100 | Quality Level 100 | Quality Level 200 | Quality Level 200 |
| storage temp. −20°C | storage temp. −20°C | storage temp. −20°C | storage temp. −20°C |
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
J W Darges et al.
Advances in experimental medicine and biology, 400A, 387-392 (1997-01-01)
The sphingosine analog L-threo-dihydrosphingosine has been shown to inhibit protein kinase C (PKC) isoenzymes in mixed micelle and vesicle assays. This compound also inhibited the reactive oxygen intermediates (ROI) released from isolated neutrophils (IC50 approximately 2 microM) and phorbol ester-induced
G K Schwartz et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 3(4), 537-543 (1997-04-01)
We performed a pilot clinical trial with safingol (L-threo-dihydrosphingosine), a protein kinase C-specific inhibitor that potentiates the effect of doxorubicin (DOX) in tumor-bearing animals. Safingol was initially administered as a 1-h infusion at escalating doses. Fourteen days later, patients received
Yi-Hsin Hsu et al.
Cancer research, 74(17), 4822-4835 (2014-06-28)
Triple-negative breast cancer (TNBC) is a highly heterogeneous and recurrent subtype of breast cancer that lacks an effective targeted therapy. To identify candidate therapeutic targets, we profiled global gene expression in TNBC and breast tumor-initiating cells with a patient survival
Número de artículo de comercio global
| SKU | GTIN |
|---|---|
| D4681-1MG | 04061833574034 |